Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk · Investor's Business Daily

In This Article:

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.